In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Durect Corp.

www.durect.com

Latest From Durect Corp.

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A

Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

US FDA Reprimands Arog Pharmaceuticals For Promo Of Investigational AML Drug

Third enforcement letter of the year cites meeting exhibit and webpage that suggest crenolanib is safe and effective for an unapproved use.

Advertising, Marketing & Sales Enforcement
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Site Specific
      • Transdermal
  • Therapeutic Areas
  • Hepatic (Liver)
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Durect Corp.
  • Senior Management
  • James E Brown, DVM, Pres. & CEO
    Michael H Arenberg, CFO
    WeiQi Lin, MD, PhD, SVP, R&D, R&D Bus. Dev.
    Robert M Janosky, VP, Strategic Planning & Bus. Dev.
  • Contact Info
  • Durect Corp.
    Phone: (408) 777-1417
    10260 Bubb Rd.
    Cupertino, CA 95014-4166
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register